Monoclonal antibodies (mAbs) are medications that target specific proteins to help reduce inflammation in people with severe asthma. The FDA has approved six mAbs for asthma treatment so far.

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority ...

Unlike their predecessors—mAbs of animal origin, or humanized or synthetic mAbs—YUMAB’s fully human mAbs maximize epitope diversity while minimizing immunogenicity and thus adverse effects.